October 17, 2006

K063190

10. 510(k) SUMMARY

Page 10/2

10.1 Summary Information

10.1.1 Submitter's Name and Address

Noble Fiber Technology 300 Palm Street Scranton, PA 18505 AUG 2 1 2007

Contact Person and telephone number:

William McNally

Telephone: 877-978-2842 Telefax: 877-978-2842

Date Summary was Prepared

October 17, 2006

10.1.2 Name of Device

Trade Name:

SILVERSEAL® Wound Packing Strip

with X-Static®

Common Name:

Silver-nylon packing strip dressing

Classification Name:

Wound dressing

Classification:

FRO

10.1.3 Identification of predicate device to which substantial equivalence is being claimed

SILVERSEAL® Wound Packing Strip with X-Static® is a flexible, non-adherent, protective dressing consisting of nylon fibers with a metallic silver surface. It is substantially equivalent to Silverlon Wound Packing Strip (K984210), Dynarex Iodoform Packing Strip (K012816), Medline Wound Packing Strip (K052720); SILVERSEAL® Contact Wound Dressing with X-Static® (K033587), Silverseal® Burn Dressing with X-Static (K050649), with respect to functional design, performance, and intended use as these presently distributed devices

10.1.4 Device Description

Explanation of how the device functions: SILVERSEAL® Wound Packing Strip with X-Static® are designed to intimately contact the wound as a primary dressing and permit the passage of fluids. The silver provides effective protection of the dressing against microbial contamination.

510(k) Premarket Notification Silverseal® Wound Packing Strip with X-Static

K063190 Page 2 0 7 2 October 17, 2006

Basic scientific concepts that form the basis for the device: The nylon fabric permits the passage of oxygen and fluids to and from the wound. The surface of the nylon fibers in SILVERSEAL® Wound Packing Strip with X-Static® consists of a thin layer of metallic silver containing approximately 1.5% silver oxide that provides effective protection of the dressing against microbial contamination.

Significant physical and performance characteristics of the device such as device design, materials used, and physical properties: SILVERSEAL® Wound Packing Strip with X-Static are made of flexible, sterile, non-adherent fabric consisting of a knitted continuous nylon fiber substrate with a metallic silver surface containing approximately 1.5% silver oxide.

10.1.5 Statement of the intended use of the device, including general description of the conditions the device will mitigate and the patient population for which the device is intended

Silverseal® Wound Packing Strip with X-Static® are intended for the control of local wound bleeding and nasal hemorrhage, and to encourage draining by wicking fluids from a body cavity, infected area, or abscess, and to help remove necrotic tissue from ulcers or other infected wounds when used as a wet-to-dry packing.

10.1.16 Statement of how the technological characteristics of the device compare to those of the predicate device

The technological characteristics of the device, such as flexible primary contact wound dressing, permeability to oxygen and fluids, and protection against microbial contamination of the dressing that are substantially equivalent to the predicate devices cited.

10.2 Assessment of Performance Data

SILVERSEAL® Wound Packing Strip with X-Static® were subjected to standard in vivo biocompatibility tests including cytotoxicity, sensitization, and acute intracutaneous reactivity. All tests were performed in accordance with Part-10993 of the International Standard Organization (ISQ) Standard (Biological Evaluation of Medical Devices) by North American Science Associates, Inc. (NAMSA). The studies indicated that SILVERSEAL® Wound Packing Strip with X-Static® are safe for their intended use.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 2 1 2007

Noble Fiber Technologies, Inc. % Ms. Patricia Davidson 300 Palm Street Scranton, Pennsylvania 18505

Re: K063190

Trade/Device Name: SILVERSEAL® Wound Packing Strips with X-Static®

Regulatory Class: Unclassified

Product Code: FRO Dated: July 27, 2007 Received: July 31, 2007

Dear Ms. Davidson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally

Page 2 – Ms. Patricia Davidson

marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely your

Mark N. Melkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

Indications for Use

K063190 510(k) Number (if known):

Device Name:

SILVERSEAL® Wound Packing Strips with X-Static®

Indications For Use:

Silverseal® Wound Packing Strips with X-Static® are intended for the control of local wound bleeding and nasal hemorrhage, and to encourage draining by wicking fluids from a body cavity, infected area, or abscess, and to help remove necrotic tissue from ulcers or other infected wounds when used as a wet-to-dry packing.

Prescription Use XXX (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

> Concurrence of CDRH, Office of Device Evaluation (ODE) Page 1 of 1

wision Sign-Off)

Division of General, Restorative,

and Neurological Devices 1663140

510(k) Number__